Product Overview
[Drug Name]
Generic Name: Pantoprazole Sodium Enteric-Coated Capsules
Trade Name: DiNuoLuoKe Pantoprazole Sodium Enteric-Coated Capsules (40mg x 12 capsules)
Pinyin Full Code: DiNuoLuoKe ZuoTuoLaZuoNaChangRongJiaoNang 40mg x 12Li
[Main Ingredient]
Pantoprazole Sodium
[Properties]
This product is an enteric-coated capsule containing a white or off-white powder.
[Indications/Main Functions]
Indicated for active peptic ulcers (gastric and duodenal ulcers), reflux esophagitis, and Zollinger-Ellison syndrome.
[Specifications]
40mg x 12 capsules (DinoLuoKe)
[Dosage and Administration]
Oral administration: 40mg (1 capsule) daily before breakfast. The treatment course for duodenal ulcers is usually 2-4 weeks, while the treatment course for gastric ulcers and reflux esophagitis is usually 4-8 weeks.
[Adverse Reactions]
Occasional symptoms include dizziness, insomnia, drowsiness, nausea, diarrhea, constipation, rash, and muscle pain. High doses may cause cardiac arrhythmias, elevated aminotransferases, changes in renal function, and decreased granulocytes.
[Contraindications]
1. Contraindicated for use by lactating women and women within three months of pregnancy. 2. Contraindicated for use by those with allergies to this product.
[Drug Interactions]
Drug interactions may occur if used with other medications. Please consult your physician or pharmacist for details.
[Precautions]
1. This product is an enteric-coated formulation; do not chew it before taking. 2. When gastric ulcers are suspected, cancer should be ruled out first, as this product may alleviate symptoms and delay diagnosis. 3. Use with caution in patients with hepatic and renal impairment. In severe liver disease, the clearance of this product is delayed, so the dosage should be reduced. 4. This product should not be taken with other antacids or acid suppressants. To prevent excessive acid suppression, high doses and long-term use are recommended for conditions such as peptic ulcers, with the exception of Zollinger-Ellison syndrome.
[Children's Use]
Follow your doctor's instructions.
[Elderly Patients' Use]
Follow your doctor's instructions.
[Pharmacology and Toxicology]
This drug is a proton pump inhibitor of gastric parietal cells. It is relatively stable under neutral and weakly acidic conditions and rapidly activated under strongly acidic conditions. Its pH-dependent activation makes it highly selective for H+ and K+-ATPase. This drug specifically inhibits H+ and K+-ATPases located in the secretory microtubules and tubulo-vacuoles of the apical membrane of parietal cells, causing irreversible inhibition of these enzymes and thereby effectively suppressing gastric acid secretion. Because H+ and K+-ATPases are the final step in the acid secretion process of parietal cells, this drug has a strong acid-suppressing effect. It not only non-competitively inhibits gastric acid secretion induced by gastrin, histamine, and choline, but also inhibits basal gastric acid secretion that is not affected by choline or H2 receptor blockers. This drug has the advantage of minimal drug-drug interactions when used in combination with other drugs. This product is metabolized through System I of the cytochrome P450 enzyme system within liver cells, and can also be metabolized through System II. When used in combination with other drugs metabolized by the P450 enzyme system, this product's metabolism can proceed through System I, making it less likely to compete with drug-metabolizing enzymes and reducing drug-drug interactions in the body. It is non-mutagenic, carcinogenic, or teratogenic.
